• 1
    Bays H, Stein EA. Pharmacotherapy for dyslipidemia – current therapies and future agents. Expert Opin Pharmacother 2003; 4: 190138.
  • 2
    Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, Hailpern SM, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell C, Roger V, Sorlie P, Steinberger J, Thom T, Wilson M, Hong Y. Heart disease and stroke statistics – 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; I117: e25e146.
  • 3
    Fuster V, Moreno PR, Fayad ZA, Corti R, Badimon JJ. Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol 2005; 46: 93754.
  • 4
    Ross R. Mechanisms of disease – atherosclerosis – an inflammatory disease. N Engl J Med 1999; 340: 11526.
  • 5
    Fuster V, Fayad ZA, Badimon JJ. Acute coronary syndromes: biology. Lancet 1999; 353: (Suppl. 2): SII5SII9.
  • 6
    Rhoads GG, Gulbrandsen CL, Kagan A. Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men. N Engl J Med 1976; 294: 2938.
  • 7
    Sikorski JA. Oral cholesteryl ester transfer protein (CETP) inhibitors: a potential new approach for treating coronary artery disease. J Med Chem 2006; 49: 122.
  • 8
    Parini P, Rudel LL. Is there a need for cholesteryl ester transfer protein inhibition? Arterioscler Thromb Vasc Biol 2003; 23: 3745.
  • 9
    Watts GF. The Yin and Yang of cholesteryl ester transfer protein and atherosclerosis. Clin Sci 2002; 103: 5957.
  • 10
    Barter PJ, Brewer HB, Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein – a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003; 23: 1607.
  • 11
    Kastelein JJP, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, Revkin JH, Grobbee DE, Riley WA, Shear CL, Duggan WT, Bots ML. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007; 356: 162030.
  • 12
    Nissen SE, Tardif J, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007; 356: 130416.
  • 13
    Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 210922.
  • 14
    Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, Shear CL, Duggan WT, Vicari RM, Grobbee DE, Kastelein JJ. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007; 370: 15360.
  • 15
    Joy T, Hegele RA. The end of the road for CETP inhibitors after torcetrapib? Curr Opin Cardiol 2009; 24: 36471.
  • 16
    Neeli H, Rader DJ. Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib? Cardiol Clin 2008; 26: 53746.
  • 17
    Rennings AJM, Stalenhoef AFH. JTT-705: is there still future for a CETP inhibitor after torcetrapib? Expert Opin Investig Drugs 2008; 17: 158997.
  • 18
    Rano TA, Sieber-McMaster E, Pelton PD, Yang M, Demarest KT, Kuo GH. Design and synthesis of potent inhibitors of cholesteryl ester transfer protein (CETP) exploiting a 1,2,3,4-tetrahydroquinoline platform. Bioorg Med Chem Lett 2009; 19: 245660.
  • 19
    Kuo GH, Rano T, Pelton P, Demarest KT, Gibbs AC, Murray WV, Damiano BP, Connelly MA. Design, synthesis, and biological evaluation of (2R,alpha S)-3,4-dihydro-2-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-5-[3-(trifluoromethoxy)-phenyl]-alpha-(trifluoromethyl)-1(2H)-quinolineethanol as potent and orally active cholesteryl ester transfer protein inhibitor. J Med Chem 2009; 52: 176872.
  • 20
    Schmeck C, Gielen-Haertwig H, Vakalopoulos A, Bischoff H, Li V, Wirtz G, Weber O. Novel tetrahydrochinoline derived CETP inhibitors. Bioorg Med Chem Lett 2010; 20: 17403.
  • 21
    Weber O, Willmann S, Bischoff H, Li V, Vakalopoulos A, Lustig K, Hafner F-T, Heinig R, Schmeck C, Buehner K. Prediction of a potentially effective dose in humans for BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein (CETP) by allometric species scaling and combined pharmacodynamic and physiologically-based pharmacokinetic modelling. Br J Clin Pharmacol 2011; 73: 21931.
  • 22
    Brueckner D, Hafner FT, Li V, Schmeck C, Telser J, Vakalopoulos A, Wirtz G. Dibenzodioxocinones–a new class of CETP inhibitors. Bioorg Med Chem Lett 2005; 15: 36114.
  • 23
    Bisgaier CL, Minton LL, Essenburg AD, White A, Homan R. Use of fluorescent cholesterylester mircoemulsions in cholesteryl ester transfer protein assays. J Lipid Res 1993; 34: 162534.
  • 24
    Lutfullin A, Kuhlmann J, Wensing G. Adverse events in healthy volunteers participating in phase I clinical trials: a single center 5 years survey in 1,559 subjects. Int J Clin Pharmacol Ther 2005; 43: 21726.
  • 25
    Wensing G, Igrhayeb IA, Boix O, Boettcher M. The safety of healthy volunteers in first in man trials – an analysis of studies conducted at the Bayer in-house ward from 2000–2005. Int J Clin Pharmacol Ther 2010; 48: 56370.
  • 26
    Syeda F, Senault C, Delplanque B, Le Roy B, Thaminy A, Gripois D, Blouquit MF, Ruelland A, Mendy F, Lutton C. Postprandial variations in the cholesteryl ester transfer protein activity, phospholipid transfer protein activity and plasma cholesterol efflux capacity in normolipidemic men. Nutr Metab 2003; 13: 2836.
  • 27
    Clark RW, Sutfin TA, Ruggeri RB, Willauer AT, Sugarman ED, Magnus-Aryitey G, Cosgrove PG, Sand TM, Wester RT, Williams JA, Perlman ME, Bamberger MJ. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol 2004; 24: 4907.